Advances in Cyclodextrins and Their Derivatives in Nano-Delivery Systems

Today's cyclodextrin,

Today’s cyclodextrin is an easy review on Advances in Cyclodextrins and Their Derivatives in Nano-Delivery Systems

The areas covered include nanospheres, nano-sponges, nanogels, cyclodextrin metal–organic frameworks, liposomes, and emulsions, providing a comprehensive and in-depth understanding of the design and development of nano-delivery systems.

Advances in Cyclodextrins and Their Derivatives in Nano-Delivery Systems (mdpi.com)

Encapsulation of 5-fluorouracil in cholesteryl-modified cyclodextrin: thermal, spectral, and computational assessment of drug inclusion efficiency

drug development, Today's cyclodextrin

Today’s cyclodextrin:
I have seen many visualizations and artwork of cyclodextrins so far, yet this “jellyfish” cover caught my eye.

Cholesteryl-modified cyclodextrin (also a great idea) to capture and deliver 5-fluorouracil.

Encapsulation of 5-fluorouracil in cholesteryl-modified cyclodextrin: thermal, spectral, and computational assessment of drug inclusion efficiency – Journal of Materials Chemistry B (RSC Publishing)

FORMULATION DEVELOPMENT – Solubility-Enhancing Technologies in Pharmaceutical Development, a Mini-Review

Egyéb kategória

Great article in this month’s issue of Drug Development & Delivery featuring cyclodextrins and other solubilization techniques.

Ardena‘s Drug Product team, led by Vincent Levet (Director, Formulation Development and Production) and Timothy Pas (Group Leader, Formulation Development and Production), has just published this technical article that explores innovative formulation strategies aimed at addressing solubility and bioavailability challenges in poorly soluble drugs. The article focuses on advanced techniques like Amorphous Solid Dispersions (ASDs), lipid-based formulations, Nanosuspensions, and hashtag#Cyclodextrin complexes.

The team highlights how these approaches can accelerate time-to-market while ensuring optimal therapeutic outcomes.

FORMULATION DEVELOPMENT – Solubility-Enhancing Technologies in Pharmaceutical Development, a Mini-Review (drug-dev.com)

COMPOSITIONS OF HYDROXYPROPYL-BETA-CYCLODEXTRIN AND METHODS OF PURIFYING THE SAME

Today's cyclodextrin

Today’s cyclodextrin is yet another fascinating patent from Beren Therapeutics, and my old colleague, Gábor Benkovics PhD on HPBCD.

This time they show methods of isomerically purifying a mixture of hydroxypropyl-β-cyclodextrins, with the goal of creating safer and better active ingredients from “common” cyclodextrins.

Way to go guys!

Beren’s former patents detailed the use of HPBCD in various hashtag#cardiovascular conditions involving hashtag#cholesterol homeostasis such as hashtag#atherosclerosis or familiar hypercholesterolemia.

US20240270877 COMPOSITIONS OF HYDROXYPROPYL-BETA-CYCLODEXTRIN AND METHODS OF PURIFYING THE SAME (wipo.int)

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

drug development, Today's cyclodextrin

Today’s cyclodextrin update brings news of the 2nd oral drug to be marketed using sulfobutylether-beta-CD.

Axsome Therapeutics, Inc. has announced that the U.S. FDA has acknowledged the resubmission of the NDA for AXS-07, an oral, rapidly absorbed, multi-mechanistic investigational medicine for the acute treatment of migraine. AXS-07 combines MoSEIC™ meloxicam and rizatriptan, offering a new molecular entity for migraine treatment enabled by Axsome’s innovative technology.

About Migraine
Migraine is a serious neurological condition characterized by recurrent attacks of pulsating, often severe and disabling head pain associated with nausea, sensitivity to light, and sensitivity to sound. An estimated 39 million Americans suffer from migraine, and it is the leading cause of disability among neurological disorders in the United States according to the American Migraine Foundation. Published surveys of migraine sufferers found that more than 70% are not fully satisfied with their current treatment and desire therapies that work faster, more consistently, and result in less symptom recurrence.

About AXS-07
AXS-07 is a novel, oral, rapidly absorbed, multi-mechanistic investigational medicine for the acute treatment of migraine, consisting of MoSEIC™ meloxicam and rizatriptan. Meloxicam is a new molecular entity for migraine enabled by Axsome’s MoSEIC (Molecular Solubility Enhanced Inclusion Complex) technology, which results in rapid absorption of meloxicam while maintaining a long plasma half-life. Meloxicam is a COX-2 preferential non-steroidal anti-inflammatory drug and rizatriptan is a 5-HT1B/1D agonist. AXS-07 is designed to provide rapid, enhanced and consistent relief of migraine, with reduced symptom recurrence. AXS-07 is covered by more than 200 issued U.S. and international patents which provide protection until at least 2038. AXS-07 is not approved by the FDA.

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine | Axsome Therapeutics, Inc. (gcs-web.com)

Role of Cyclodextrin Cross-Linker Type on Steroid Hormone Micropollutant Removal from Water Using Composite Nanofiber Membrane

Today's cyclodextrin

Today’s cyclodextrin is about water purification.

What if we could make our water cleaner using a safer, composite nanofiber membrane?

This study investigates how different cross-linkers affect the stability and micropollutant removal efficiency of β-cyclodextrin polymers in composite nanofiber membranes. It finds that triphenylolmethane triglycidyl ether (TPTE) and trimethylolpropane triglycidyl ether (TMTE) are effective alternatives to the more toxic epichlorohydrin (EP) for removing steroid hormones from water.

Check out the paper by Han-Ya Lin (with Akhil Gopalakrishnan, PhD in the photo) et al., “Role of Cyclodextrin Cross-Linker Type on Steroid Hormone Micropollutant Removal from Water Using Composite Nanofiber Membrane,” here: https://lnkd.in/diXpHPWK

Role of Cyclodextrin Cross-Linker Type on Steroid Hormone Micropollutant Removal from Water Using Composite Nanofiber Membrane | ACS Applied Polymer Materials

Cyclodextrins: Establishing building blocks for AI-driven drug design by determining affinity constants in silico

Today's cyclodextrin,

Today’s cyclodextrin:
Check out this fascinating paper guiding us to the future of CDs:

AI-driven cyclodextrin drug design

Fascinating research by Amelia Anderson & Matthew “Oki” O’Connor from Cyclarity Therapeutics and Angel Piñeiro & Rebeca Garcia-Fandino from Universidad de Santiago de Compostela

Computational methods represent an exceptional complement to in vitro assays because they can be employed for existing and hypothetical molecules, providing high resolution structures in addition to a mechanistic, dynamic, kinetic, and thermodynamic characterization.

Bridging computational methods with complex molecular interactions, this research enables predictive CD designs for diverse applications. Moreover, the high reproducibility, sensitivity, and cost-effectiveness of the studied methods pave the way for extensive studies of massive CD-ligand combinations, enabling AI algorithm training and automated molecular design.

Cyclodextrins: Establishing building blocks for AI-driven drug design by determining affinity constants in silico – Computational and Structural Biotechnology Journal (csbj.org)

CPHI 2024: The Premier Event for the Pharmaceutical Industry is Just Around the Corner

news

The most anticipated pharmaceutical event of the year is fast approaching! CPHI 2024, set to take place in Milan from October 8-10, is the world’s largest pharmaceutical exhibition. This event is a unique convergence of six individual pharma sectors, covering every aspect of the industry—from ingredients and FDF to machinery, packaging, outsourcing, and biopharmaceuticals.

What to Expect at CPHI 2024

This year’s CPHI is shaping up to be bigger and better than ever. Here’s what attendees can look forward to:

  • 62,000 attendees from across the globe
  • 2,400 exhibitors showcasing the latest innovations and services
  • 166 countries represented, making it a truly global gathering
  • 150+ expert speakers sharing insights and trends shaping the future of pharma

For those who have previously attended a CPHI event, you’ll know that it’s tailored specifically for professionals in the pharmaceutical industry. Whether you’re looking to network, learn, or explore new business opportunities, CPHI is the place to be.

Spotlight on Cyclodextrins

Among the myriad of products and technologies on display, cyclodextrins will feature prominently at CPHI 2024. Expect to meet a wide range of users and manufacturers of cyclodextrins, including:

And, of course, CarboHyde will be there too. Our team will be well-represented, with CFO Gergely Toth, COO Tamás Vargadi, and Tamas Sohajda all attending the event. We’re excited about the opportunity to engage with industry peers and discuss potential collaboration on cyclodextrin projects.

Let’s Connect at CPHI 2024

If you’re planning to attend CPHI in Milan, we would love to catch up with you. This event presents a fantastic opportunity to plan and strategize around cyclodextrin-related projects. We believe that face-to-face interactions at such a prestigious event can pave the way for meaningful collaborations.

We look forward to seeing you there!

Preparation of Carvacrol β-Cyclodextrin Inclusions and 1-Methylcyclopropene-α-CD Coated Paper by Water-Free Method for Postharvest Preservation of Peach

Today's cyclodextrin

Today’s cyclodextrin: is a packaging/food preservation application

Where Carvacrol β-Cyclodextrin Inclusions and 1-Methylcyclopropene-α-CD Coated Paper are for post-harvest preservation of peach.

Carvacrol essential oil has broad-spectrum antibacterial properties, but it is volatile and unstable for long-term storage and use. In the present study, carvacrol was encapsulated with β-cyclodextrin to improve its relevant properties.

PEG was used to form the film in the anhydrous condition, and the compound and ethylene inhibitor 1-methylcyclopropene (1-MCP) were included to obtain the film-coated paper.

This study provides a solution for preparing controlled-release coated paper with essential oils and 1-MCP bioactives to extend the shelf life of fruits and vegetables.

Preparation of Carvacrol β-Cyclodextrin Inclusions and 1-Methylcyclopropene-α-CD Coated Paper by Water-Free Method for Postharvest Preservation of Peach | Food and Bioprocess Technology (springer.com)

β-Cyclodextrin nano-encapsulated carvacrol inclusion complexes improve postharvest quality of limes (Citrus latifolia Tanaka) (usda.gov)